Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib rollover continuation study for solid tumors or leukemia
NL-OMON38447Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms and leukemia, sponsored by GSK. Started Nov 2013; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasmsleukemia
Beyond the preview
Go deeper on NL-OMON38447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38447.